AFB Susceptibility MGIT (13 Drugs Panel)

Mycobacterium tuberculosis susceptibility to 13 distinct anti-tuberculosis medications is assessed using the AFB Susceptibility MGIT (Mycobacteria Growth Indicator Tube) 13 Drugs test. By detecting drug-resistant microorganisms, this test aids in directing efficient treatment.

To guarantee proper antibiotic treatment, patients with a TB diagnosis or those suspected of having multidrug-resistant TB (MDR-TB) should have this test performed.

In an MGIT system, a sample—typically sputum—is cultivated to identify bacterial growth and assess how well 13 distinct medications suppress it.

If the result is positive, it means that the bacteria are resistant to one or more of the medications that were tested, which means that the treatment plan needs to be modified to incorporate other, more effective antibiotics.

Results guide the choice of antibiotics, ensuring that the most effective drugs are used, thereby reducing the risk of treatment failure or disease progression.